Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males and females, 40+ years in general good health as assessed by the investigator.~2. BCC (subtype: superficial or nodular) confirmed histologically by diagnostic shave biopsy at the Screening Visit~3. Primary BCC (i.e., no previous treatment)~4. Lesion size ≥ 4 mm2 or 2 x 2 mm and ≤ 169 mm2 or 13 x 13 mm~5. Participant must have no other clinically significant abnormal findings in his/her medical history, physical examination or clinical laboratory test results as assessed by the investigator~6. Negative urine pregnancy at study entry for female of child bearing potential~7. Men and women of child-producing potential must agree to use adequate contraception according to standard instructions by the investigator until the completion of the study~8. Participant must to be willing to adhere to the instructions of the investigator and his or her research team~9. Participant must sign an Informed Consent Form prior to any study specific procedures and entry into the study~Exclusion Criteria:~1. Evidence of clinically significant, unstable medical conditions as assessed by the investigator~2. Excisional biopsy performed on the lesion to be treated in this study~3. Recent therapy(ies) to the BCC treatment area~4. Recurrent BCC (previously treated) at the site presented for treatment~5. BCC lesion to be treated is located in an area where excisional biopsy is undesired or aesthetically unacceptable to the participant~6. Previously demonstrated sensitivity to doxorubicin or carboxymethyl cellulose.~7. Participant with other active malignancies with the exception of non-metastatic prostate cancer and carcinoma in situ of the skin and cervix~8. Concomitant disease requiring systemic immunosuppressive treatment~9. Genetic skin cancer disorder, e.g., basal cell nevus syndrome~10. Participant is pregnant or breastfeeding~11. Treatment with another investigational drug, device, or other intervention within 3 months prior to the Screening Visit~12. Existing condition or treatment within 3 months prior to the Screening Visit that may have impact on clinical outcome for the treatment of BCC or delay in wound healing from the elliptical excision

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo-containing MNA (Type: PLACEBO_COMPARATOR): Placebo
- 25 µg Doxorubicin-containing MNA (Type: EXPERIMENTAL): D-MNA's containing 25 µg of doxorubicin hydrochloride
- 50 µg Doxorubicin-containing MNA (Type: EXPERIMENTAL): D-MNA's containing 50 µg of doxorubicin hydrochloride
- 100 µg Doxorubicin-containing MNA (Type: EXPERIMENTAL): D-MNA's containing 100 µg of doxorubicin hydrochloride
- 200 µg Doxorubicin-containing MNA (Type: EXPERIMENTAL): D-MNA's containing 200 µg of doxorubicin hydrochloride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility